Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CTXR
CITIUS PHARMACEUTICALS, INC.
NASDAQ
$0.60
▼ DOWN 4.28% (-0.03)

KEY STATISTICS

Market Cap$6.73 M
52w High$2.19
52w Low$0.47
Dividend Yield—
Frequency—
P/E-0.36
Volume361.73K
Shares Out.11.17M

COMPANY

LEADERSHIP

Leonard L. Mazur
CHIEF EXECUTIVE
Leonard L. Mazur

COMPENSATION 2026

Salary$475,000
Stock Awards$0
Incentive Plan Pay$213,750
All Other Comp.$0
Total$3,521,268

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 2, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
23

UPCOMING EARNINGS

DateDec 17, 2026
DayThursday
Rev. Est.$2.94M
DEC
17
THU

SPLIT RECORD

DATETYPERATIO
2017-06-09Reverse1:15

PRICE

$0.60 ▼ DOWN 4.28% (−$0.03)
OVERLAYS
$0.60$0.61$0.639:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM0.60

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com ↗

Citius Pharmaceuticals, Inc. develops and commercializes critical care and anti-infective products, including antibiotic lock solutions, tissue expander wraps, topical treatments, stem cell therapies, and targeted cancer treatments.

INDUSTRY

Biotechnology

A PRODUCT CITIUS PHARMACEUTICALS, INC. IS KNOWN FOR

LYMPHIR™ (denileukin diftitox-cxdl)
LYMPHIR™ (denileukin diftitox-cxdl)

LYMPHIR™ is an FDA-approved targeted immunotherapy for relapsed/refractory Stage I-III CTCL, launched in the U.S. in December 2025 by Citius Oncology, marking its transition to a revenue-generating commercial-stage biopharmaceutical company.

COMPETITORS

COMPETITOR
BHC COMPARE
BMY COMPARE
MRK COMPARE
SNGX COMPARE
TAK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 197.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
33.98%
HOLDERS
59
TOP 12 OF 59 · RANKED BY POSITION SIZE
Blackrock Inc.
1.8M sh · $1.05M
Heights Capital Management, Inc
799.9K sh · $621.55K
Geode Capital Management, LLC
246.2K sh · $221.56K
Vanguard Group Inc
199.3K sh · $154.82K
Argent Wealth Management LLC
164.4K sh · $178K
Key Bridge Compliance, LLC
154.1K sh · $105.49K
Xtx Topco Ltd
107.1K sh · $83.23K
Ubs Group AG
76.4K sh · $59.39K
Blackrock, Inc.
69.9K sh · $86.61K
Two Sigma Investments, LP
60.8K sh · $47.27K
Hrt Financial LP
60.3K sh · $54K
Freed Investment Group
52.9K sh · $107K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mazur Leonard L
Purchase · 125.5K shares
2025-08-08
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mazur Leonard L
Purchase · 89.4K shares
2025-08-08

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
D. Boral Capital BUY

SECTORS PEERS

PEERPRICE
APLM$26.60COMPARE
DARE$0.73COMPARE
LNAI$2.37COMPARE
ICU$3.09COMPARE
ADTX$0.01COMPARE
MBRX$0.65COMPARE
FBLG$1.44COMPARE
CRIS$1.49COMPARE